Evidence map›Paper›PMID 31260313›Full record

ArticleThe journal of physical chemistry. B2019

Protein/Ice Interaction: High-Resolution Synchrotron X-ray Diffraction Differentiates Pharmaceutical Proteins from Lysozyme.

Bakul Bhatnagar, Boris Zakharov, Alexander Fisyuk, Xin Wen, Fawziya Karim, Kimberly Lee, Yurii Seryotkin, Mashikoane Mogodi, Andy Fitch, Elena Boldyreva and 2 more

Open access · greenAbstract read
In one paragraph

Article in The journal of physical chemistry. B, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Bakul BhatnagarBTx PharmSci Pharmaceutical R&D , Pfizer, Inc. , One Burtt Road , Andover 01810 , Massachusetts , United States.
Boris ZakharovBoreskov Institute of Catalysis, Siberian Branch of the RAS , Lavrentieva Avenue, 5 , Novosibirsk 630090 , Russia.
Alexander FisyukLaboratory of Organic Synthesis, Chemistry Department , Omsk F.M. Dostoevsky State University , Prospect Mira 55a , Omsk 644053 , Russian Federation.ORCID 0000-0001-6191-9297
Xin WenDepartment of Chemistry and Biochemistry , California State University, Los Angeles , Los Angeles 90032 , California , United States.
Fawziya KarimBTx PharmSci Pharmaceutical R&D , Pfizer, Inc. , One Burtt Road , Andover 01810 , Massachusetts , United States.
Kimberly LeeDepartment of Chemistry and Biochemistry , California State University, Los Angeles , Los Angeles 90032 , California , United States.
Yurii SeryotkinNovosibirsk State University , Pirogova Street, 2 , Novosibirsk 630090 , Russia.
Mashikoane MogodiThe European Synchrotron Radiation Facility (ESRF) , 71 Avenue des Martyrs , Grenoble 38043 , France.
Andy FitchThe European Synchrotron Radiation Facility (ESRF) , 71 Avenue des Martyrs , Grenoble 38043 , France.
Elena BoldyrevaBoreskov Institute of Catalysis, Siberian Branch of the RAS , Lavrentieva Avenue, 5 , Novosibirsk 630090 , Russia.ORCID 0000-0002-1401-2438
Anastasia KostyuchenkoLaboratory of New Organic Materials , Omsk State Technical University , 11 Mira Avenue , Omsk 644050 , Russian Federation.
Evgenyi ShalaevAllergan Inc. , Pharmaceutical Development , 2525 DuPont Dr , Irvine 92612 , California , United States.ORCID 0000-0002-8611-0627
Novosibirsk State University · RUCalifornia State University Los Angeles · USEuropean Synchrotron Radiation Facility · FROmsk State Technical University · RUPfizer (United States) · USDuPont (United States) · US

Funding

IDENTIFICATION AND MOLECULAR BASIS FOR EFFICIENT ANTIFREEZE PROTIEN ENHANCERSSC3GM086249 · NIGMS · CALIFORNIA STATE UNIVERSITY LOS ANGELES · PI WEN, XIN · 2009 to 2023
$1.7M
NIGMS NIH HHS SC3 GM086249
6 · The paper itself

Abstract

Protein/ice interactions are investigated by a novel method based on measuring the characteristic features of X-ray diffraction (XRD) patterns of hexagonal ice (Ih). Aqueous solutions of four proteins and other solutes are studied using high-resolution synchrotron XRD. Two pharmaceutical proteins, recombinant human albumin and monoclonal antibody (both at 100 mg/mL), have a pronounced effect on the properties of ice crystals, reducing the size of the Ih crystalline domains and increasing the microstrain. Lysozyme (100 mg/mL) and an antifreeze protein (1 mg/mL) have much weaker impact on Ih. Neither of the proteins studied exhibit preferred interactions with specific crystalline faces of Ih. It is proposed that the pharmaceutical proteins interact with ice crystals indirectly by accumulating in the quasi-liquid layer next to ice crystallization front, rather than directly, via a sorption on ice crystals. This is the first report, to the best of our knowledge, of major difference in the protein/ice interaction between non-antifreeze proteins. Another important finding is a detection of a second (minor) population of ice crystals, which is tentatively identified as a high-pressure form of ice, possibly IceIII or IceIX. This finding highlights a potential role of mechanical stresses in freeze-induced destabilization of proteins.

Indexed as

IceAntibodies, MonoclonalAntifreeze ProteinsHumansMuramidaseSerum Albumin, HumanX-Ray DiffractionAntibodies, MonoclonalAntifreeze ProteinsIceMuramidaseSerum Albumin, Human

Identifiers

PMID31260313
PMCPMC9188813
OpenAlexW2953387380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.